Filtered By:
Condition: Thrombosis
Drug: Dexamethasone
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 51 results found since Jan 2013.
Cn-14 * retrospective analysis of ischemic cerebral strokes in patients diagnosed with a glioblastoma during the course of a bevacizumab treatment
Bevacizumab is an anti-vascular endothelial growth factor approved in the treatment of recurrent glioblastoma. It prolongs progression-free survival, improes radiologic response and contributes to reduce the dose of dexamethasone required to control peritumoral edema. Arterial and venous thromboembolic events represent significant toxicities related to the use of angiogenesis inhibitors. Various mechanisms could be implicated in bevacizumab-related strokes, as cardioembolic, lacunar stroke related to hypertension, deep venous thrombosis passing through a patent foramen ovale, pro-coagulant effect of the underlying glioblas...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Maurice, C., Mason, W. P. Tags: COMPLICATIONS OF THERAPY AND NEUROTOXICITY Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
The Incidence of Thromboembolism for Lenalidomide Versus Thalidomide in Older Patients with Newly Diagnosed Multiple Myeloma
Conclusion: In this propensity score weighted study of older patients with newly diagnosed MM, the cumulative incidences of VTE and ATE were similarly high in both lenalidomide- and thalidomide-treatment groups. The lack of difference in overall survival should be interpreted with caution as residual confounding such as severity of disease could influence this outcome. Our results suggest that appropriate risk stratification and vigilant thromboprophylaxis remain essential for MM patients receiving all types of immunomodulatory drugs.DisclosuresGarcia: Retham Technologies LLC: Consultancy; Shingoi: Consultancy; Portola: Re...
Source: Blood - November 21, 2018 Category: Hematology Authors: Li, A., Wu, Q. V., Warnick, G., Libby, E. N., Garcia, D. A., Lyman, G. H. Tags: 901. Health Services Research-Non-Malignant Conditions: Thrombosis and Anticoagulation Source Type: research
Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications
Induction therapy in patients with multiple myeloma increases the risk of thromboembolism. We have recently shown that multiple myeloma patients tend to form denser fibrin clots displaying poor lysability. We investigated the effect of induction therapy on fibrin clot properties in multiple myeloma patients. Ex-vivo plasma fibrin clot permeability, turbidity, susceptibility to lysis, thrombin generation, factor VIII and fibrinolytic proteins were compared in 48 multiple myeloma patients prior to and following 3 months of induction therapy, mainly with cyclophosphamide-thalidomide-dexamethasone regimen. Patients on thrombop...
Source: Blood Coagulation and Fibrinolysis - August 5, 2015 Category: Hematology Tags: Original Articles Source Type: research
French Intensive Care Society, International congress - Réanimation 2016.
C, Sauneuf B, Verrier P, Pottier V, Orabona M, Samba D, Viquesnel G, Lermuzeaux M, Hazera P, Hanouz JL, Parienti JJ, Du Cheyron D, Demoule A, Clavel M, Rolland-Debord C, Perbet S, Terzi N, Kouatchet A, Wallet F, Roze H, Vargas F, Guérin C, Dellamonica J, Jaber S, Similowski T, Quenot JP, Binquet C, Vinsonneau C, Barbar SD, Vinault S, Deckert V, Lemaire S, Hssain AA, Bruyère R, Souweine B, Lagrost L, Adrie C, Jung B, Daurat A, De Jong A, Chanques G, Mahul M, Monnin M, Molinari N, Lheureux O, Trepo E, Hites M, Cotton F, Wolff F, Surin R, Créteur J, Vincent JL, Gustot T, Jacobs F, Taccone FS, Neuville M, Timsit JF, El-Hel...
Source: Australian Family Physician - May 31, 2016 Category: Primary Care Authors: Jaillette E, Girault C, Brunin G, Zerimech F, Chiche A, Broucqsault-Dedrie C, Fayolle C, Minacori F, Alves I, Barrailler S, Robriquet L, Delaporte E, Thellier D, Delcourte C, Duhamel A, Nseir S, Valette X, Desmeulles I, Savary B, Masson R, Seguin A, Daubi Tags: Ann Intensive Care Source Type: research
Seizures during treatment of childhood acute lymphoblastic leukemia: A population-based cohort study.
CONCLUSION: Seizures are relatively common in ALL patients and occur most often in patients with PRES, SVT, or as an isolated symptom. Older children have higher risk of seizures.
PMID: 32340855 [PubMed - as supplied by publisher]
Source: European Journal of Paediatric Neurology - April 17, 2020 Category: Neurology Authors: Anastasopoulou S, Heyman M, Eriksson MA, Niinimäki R, Taskinen M, Mikkel S, Vaitkeviciene GE, Johannsdottir IM, Myrberg IH, Jonsson OG, Als-Nielsen B, Schmiegelow K, Banerjee J, Ranta S, Harila-Saari A Tags: Eur J Paediatr Neurol Source Type: research
Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship
World J Gastroenterol. 2022 Mar 21;28(11):1102-1112. doi: 10.3748/wjg.v28.i11.1102.ABSTRACTCoronavirus disease 2019 (COVID-19) is, at present, one of the most relevant global health problems. In the literature hepatic alterations have been described in COVID-19 patients, and they are mainly represented by worsening of underlying chronic liver disease leading to hepatic decompensation and liver failure with higher mortality. Several potential mechanisms used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to cause liver damage have been hypothesized. COVID-19 primary liver injury is less common than secondar...
Source: World Journal of Gastroenterology : WJG - April 18, 2022 Category: Gastroenterology Authors: Damiano D'Ardes Andrea Boccatonda Giulio Cocco Stefano Fabiani Ilaria Rossi Marco Bucci Maria Teresa Guagnano Cosima Schiavone Francesco Cipollone Source Type: research
